The progress made in understanding biology and heterogeneity of acute myeloid leukaemia (AML) has recently led to tremendous advances and possibilities for treatment individualization. This has resulted in the need for a dedicated ESMO E-learning module to contextualize many practice changing data.
After providing background information on disease heterogeneity, importance of cytogenetics, molecular data and details on risk categories, the author underpins what is relevant in terms of therapeutics: risk stratification for consolidation therapy, rational use of targeted therapy in relation to targeting based on biology, identification of the groups of patients for whom the treatment could be effective or not and subgroup analysis in clinical trials.
Furthermore, the author discusses in depth the current recommendations for induction therapy and provides the evidence from clinical trials for various drugs, disease and patient characteristics.
Available clinical data for agents that have gained recently regulatory approval are summarised. Besides covering the agents and combination regimens in terms of enhancing application of practice-changing data into clinical practice, the author also digs into a plethora of emerging therapies and analyses what to expect in the future.
This module is also an excellent summary of data in different AML patient subsets. In addition to recently emerged targeted therapies, treatment individualization and discussion on patient prognosis and outcome, the author summarizes encouraging attempts of further targeted therapies.
This module is an excellent digest for all those who would like to understand recent advances in elucidating the AML biology and genetic landscape with potentials to lead to subset specific therapies and tailor to the individual patient’s characteristics and disease.
